MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria

Phase 4
Completed
Conditions
Plasmodium Falciparum Infection
Interventions
First Posted Date
2023-03-01
Last Posted Date
2025-05-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
90
Registration Number
NCT05750459
Locations
🇺🇬

Makerere University - Infectious Diseases Institute, Kampala, Uganda

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Phase 2
Completed
Conditions
Monkeypox
Interventions
First Posted Date
2023-02-23
Last Posted Date
2025-05-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
450
Registration Number
NCT05740982
Locations
🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States

🇺🇸

Duke Vaccine and Trials Unit, Durham, North Carolina, United States

and more 15 locations

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Phase 4
Completed
Conditions
Monkeypox
Interventions
Biological: MVA-BN vaccine
First Posted Date
2023-02-21
Last Posted Date
2024-07-25
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
500
Registration Number
NCT05734508
Locations
🇨🇩

Institut National de Rescherche Biomédicale (INRB), Kinshasa, Congo, The Democratic Republic of the

🇨🇩

L'Hôpital Général de Référence de Tunda, Tunda, Congo, The Democratic Republic of the

🇨🇩

L'Hôpital Général de Référence de Kole, Kole, Congo, The Democratic Republic of the

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Phase 2
Suspended
Conditions
Acute HIV Infection
Interventions
First Posted Date
2023-02-09
Last Posted Date
2025-04-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
48
Registration Number
NCT05719441
Locations
🇺🇸

31788, Alabama CRS, Birmingham, Alabama, United States

🇺🇸

1201, University of Southern California CRS, Los Angeles, California, United States

🇺🇸

601, University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States

and more 33 locations

Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA

Phase 2
Completed
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Device: Active tcVNS or Sham tcVNS
Device: Active tcVNS
First Posted Date
2023-02-02
Last Posted Date
2025-04-25
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
18
Registration Number
NCT05710640
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

Nemours Children's Health: Department of Pediatric Rheumatology, Orlando, Florida, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

and more 4 locations

Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine

Phase 1
Active, not recruiting
Conditions
Response To Dengue Exposure
Interventions
Drug: rDENdelta30/31-7164
First Posted Date
2023-01-20
Last Posted Date
2025-05-16
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
126
Registration Number
NCT05691530
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Phase 1
Active, not recruiting
Conditions
Epstein-Barr Virus Infection
Infectious Mononucleosis
Herpesvirus
Interventions
Other: Placebo Comparator
Drug: EBV gp350-Ferritin Vaccine
First Posted Date
2023-01-13
Last Posted Date
2025-04-25
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
25
Registration Number
NCT05683834
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Daratumumab in Primary Antiphospholipid Syndrome

Phase 1
Recruiting
Conditions
Autoimmune Disorders
Interventions
First Posted Date
2023-01-05
Last Posted Date
2024-11-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
22
Registration Number
NCT05671757
Locations
🇺🇸

NYU Langone, New York, New York, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 5 locations

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

Phase 1
Recruiting
Conditions
HIV-1-infection
Interventions
Drug: Long acting CAB injectable + long acting RPV injectable
Drug: Once daily CAB tablet + RPV tablet
First Posted Date
2022-12-21
Last Posted Date
2025-01-17
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
90
Registration Number
NCT05660980
Locations
🇺🇸

Site 5030, Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States

🇺🇸

Site 6501, St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States

🇧🇼

Site 12701, Gaborone CRS, Gaborone, Botswana

and more 9 locations

A Repository to Study Host-Microbiome Interactions in Health and Disease

Recruiting
Conditions
Pregnancy
Inflammatory Diseases
Healthy Controls
Pediatric Illnesses
First Posted Date
2022-12-19
Last Posted Date
2025-04-30
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
600
Registration Number
NCT05656378
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath